Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy

Biomaterials

Volumn 34, Issue 36, 2013, Pages 9134-9141

  Kinnari, Päivi J ^a   Hyvönen, Maija L K ^a   Mäkilä, Ermei M ^a,b   Kaasalainen, Martti H ^b   Rivinoja, Antti ^a,c   Salonen, Jarno J ^b   Hirvonen, Jouni T ^a   Laakkonen, Pirjo M ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Breast cancer; Homing peptide; Nanoparticles; Nanovector; Porous silicon; Tumour targeting

Indexed keywords

ANTI-CANCER DRUG DELIVERY; BREAST CANCER; GROWTH INHIBITOR; HOMING PEPTIDE; INTRAVENOUS INJECTIONS; NANO PARTICULATES; NANOPARTICLE (NPS); NANOVECTOR;

CELLS; CHEMOTHERAPY; DRUG DELIVERY; NANOPARTICLES; PEPTIDES; POROUS SILICON;

TUMORS;

PEPTIDE; SILICON; TUMOR HOMING PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENCAPSULATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

MUS MUSCULUS;

BREAST CANCER; HOMING PEPTIDE; NANOPARTICLES; NANOVECTOR; POROUS SILICON; TUMOUR TARGETING;

ADSORPTION; ANIMALS; BLOOD PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FATTY ACID-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS; PEPTIDES; POROSITY; SILICON; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE DISTRIBUTION;

EID: 84883806964     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.08.034     Document Type: Article

References (40)

1. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. JControl Release 2010, 148:135-146.
2. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2012, 64:206-212.
3. Mcneil S.E. Nanoparticle therapeutics: a personal perspective. WIRES Nanomed Nanobiotechnol 2009, 1:264-271.
4. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
5. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
6. Pirollo K.F., Chang E.H. Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol 2008, 26:552-558.
7. Laakkonen P., Vuorinen K. Homing peptides as targeted delivery vehicles. Integr Biol 2010, 2:326-337.
8. Kukowska-Latallo J.F., Candido K.A., Cao Z., Nigavekar S.S., Majoros I.J., Thomas T.P., et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005, 65:5317-5324.
9. Bimbo L.M., Mäkilä E., Raula J., Laaksonen T., Laaksonen P., Strommer K., et al. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. Biomaterials 2011, 32:9089-9099.
10. Kinnari P., Mäkilä E., Heikkilä T., Salonen J., Hirvonen J., Santos H.A. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int J Pharm 2011, 414:148-156.
11. Limnell T., Riikonen J., Salonen J., Kaukonen A.M., Laitinen L., Hirvonen J., et al. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles. Int J Pharm 2007, 343:141-147.
12. Liu D., Mäkilä E., Zhang H., Herranz B., Kaasalainen M., Kinnari P., et al. Nanostructured porous silicon-solid lipid nanocomposite: towards enhanced cytocompatibility and stability, reduced cellular association, and prolonged drug release. Adv Funct Mater 2013, 23:1893-1902.
13. Santos H.A., Bimbo L.M., Lehto V.-P., Airaksinen A.J., Salonen J., Hirvonen J. Multifunctional porous silicon for therapeutic drug delivery and imaging. Curr Drug Discov Technol 2011, 8:228-249.
14. Sarparanta M.P., Bimbo L.M., Mäkilä E.M., Salonen J.J., Laaksonen P.H., Helariutta A.M., et al. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials 2012, 33:3353-3362.
15. Bimbo L.M., Sarparanta M., Santos H.A., Airaksinen A.J., Mäkilä E., Laaksonen T., et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010, 4:3023-3032.
16. Rytkönen J., Miettinen R., Kaasalainen M., Lehto V.-P., Salonen J., Närvänen A. Functionalization of mesoporous silicon nanoparticles for targeting and bioimaging purposes. JNanomater 2012, 2012:1-9.
17. Liu D., Bimbo L.M., Mäkilä E., Villanova F., Kaasalainen M., Herranz-Blanco B., et al. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. JControl Release 2013, 170:268-278.
18. Shahbazi M.-A., Hamidi M., Mäkilä E., Zhang H., Almeida P., Kaasalainen M., et al. The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials 2013, 34:7776-7789.
19. Nevo J., Mattila E., Pellinen T., Yamamoto D.L., Sara H., Iljin K., et al. Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance. Clin Cancer Res 2009, 15:6570-6581.
20. Hertzel A.V., Bernlohr D.A. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 2000, 11:175-180.
21. Thierry-Mieg D., Thierry-Mieg J. AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol 2006, 7(S12):1-4.
22. Nevo J., Mai A., Tuomi S., Pellinen T., Pentikäinen O.T., Heikkilä P., et al. Mammary-derived growth inhibitor (MDGI) interacts with integrin α-subunits and suppresses integrin activity and invasion. Oncogene 2010, 29:6452-6463.
23. Wang H.L., Kurtz A. Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108. Oncogene 2000, 19:2455-2460.
24. Storch J., Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 2008, 28:73-95.
25. Huynh H., Alpert L., Pollak M. Silencing of the mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res 1996, 56:4865-4870.
26. Zhang L., Cilley R.E., Chinoy M.R. Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines. JSurg Res 2000, 93:108-119.
27. Hashimoto T., Kusakabe T., Sugino T., Fukuda T., Watanabe K., Sato Y., et al. Expression of heart-type fatty acid-binding protein in human gastric carcinoma and its association with tumor aggressiveness, metastasis and poor prognosis. Pathobiology 2004, 71:267-273.
28. Hyvönen M., Virtanen J., Rivinoja A., Enbäck J., Joensuu H., Mari B., et al. The role of MDGI in glioma progression. Eur J Cancer 2012, 48:S52.
29. Laakkonen P, Ruoslahti E, Bergers G. Peptide homing to brain tumors. U.S. Patent #8188221; May 29, 2012.
30. Kaasalainen M., Mäkilä E., Riikonen J., Kovalainen M., Järvinen K., Herzig K.H., et al. Effect of isotonic solutions and peptide adsorption on zeta potential of porous silicon nanoparticle drug delivery formulations. Int J Pharm 2012, 431:230-236.
31. Bimbo L.M., Sarparanta M., Mäkilä E., Laaksonen T., Laaksonen P., Salonen J., et al. Cellular interactions of surface modified nanoporous silicon particles. Nanoscale 2012, 4:3184-3192.
32. Sarparanta M., Bimbo L.M., Rytkönen J., Mäkilä E., Laaksonen T.J., Laaksonen P., et al. Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. Mol Pharmaceutics 2012, 9:654-663.
33. Santos H.A., Riikonen J., Salonen J., Mäkilä E., Heikkilä T., Laaksonen T., et al. Invitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. Acta Biomater 2010, 6:2721-2731.
34. Baldwin L., Flanagan B.F., Hunt J.A. Flow cytometric measurement of phagocytosis reveals a role for C3b in metal particle uptake by phagocytes. JBiomed Mater Res A 2005, 73:80-85.
35. Busch W., Bastian S., Trahorsch U., Iwe M., Kühnel D., Meißner T., et al. Internalisation of engineered nanoparticles into mammalian cells invitro: influence of cell type and particle properties. JNanopart Res 2010, 13:293-310.
36. Serda R.E., Gu J., Burks J.K., Ferrari K., Ferrari C., Ferrari M. Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A 2009, 75:752-760.
37. Papadopulos F., Spinelli M., Valente S., Foroni L., Orrico C., Alviano F., et al. Common tasks in microscopic and ultrastructural image analysis using ImageJ. Ultrastruct Pathol 2007, 31:401-407.
38. Kong J., Yu S. Fourier transform infrared spectroscopic analysis of protein secondary structures protein FTIR data analysis and band assignment. Acta Biochim Biophys Sin 2007, 39:549-559.
39. Albanese A., Tang P.S., Chan W.C.W. The effect of nanoparticle size, shape, andsurface chemistry on biological systems. Annu Rev Biomed Eng 2012, 14:1-16.
40. Schipper M.L., Iyer G., Koh A.L., Cheng Z., Ebenstein Y., Aharoni A., et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 2009, 5:126-134.